According to American Cancer Society, 1 man in 9 has the probability of getting diagnosed with prostate cancer (PCa) in their lifetime. 1 out of 41 men dies due to prostate cancer every year [1]. The main radical treatment methods of prostate cancer are surgery and radiation therapy. In patients with clinically intermediate/high risk prostate cancer after initially radical treatment recurrences occur, therefore further treatment requires imaging of precise volume and localization of recurrent disease.  Recurrence of  prostate cancer can be assessed by magnetic resonance imaging (MRI) and positron emission tomography (PET/CT).  Radiopharmaceutical ¹⁸F-PSMA-1007 is a ligand, used in PET/CT and it has some advantageous characteristics in recurrent prostate cancer diagnostics, even in comparison to ⁶⁸Ga-PSMA ligand [2]. Low urinary background clearance of ¹⁸F-PSMA-1007 provides higher diagnostic value of PET/CT in evaluation of the prostate bed and pelvis in recurrent PCa patients [3]. The aim of this study was to compare the diagnostic tools -   ¹⁸F-PSMA-1007 PET/CT and MRI for evaluation of local recurrence and regional lymph nodes.